Catalyst Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 27-12-2024
- Paid Up Capital ₹ 0.35 M
as on 27-12-2024
- Company Age 4 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.55 M
as on 27-12-2024
- Revenue 208.11%
(FY 2022)
- Profit -1893.89%
(FY 2022)
- Ebitda -5654.78%
(FY 2022)
- Net Worth -399.38%
(FY 2022)
- Total Assets 474.06%
(FY 2022)
About Catalyst Lifesciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.35 M.
The company currently has active open charges totaling ₹2.55 M.
The Key Managerial Personnel (KMP) at Catalyst Lifesciences Private Limited India is Puneet Taplu as CEO. Anita Taplu, Sakshi Taplu, and Puneet Taplu serve as directors at the Company.
- CIN/LLPIN
U15549HR2020PTC088278
- Company No.
088278
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
12 Aug 2020
- Date of AGM
14 Aug 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Gurugram, Haryana, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Catalyst Lifesciences?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Puneet Taplu  | CEO | 17-Oct-2020 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Anita Taplu | Director | 12-Aug-2020 | Current |
| Sakshi Taplu | Director | 12-Aug-2020 | Current |
Financial Performance of Catalyst Lifesciences.
Catalyst Lifesciences Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 208.11% increase. The company also saw a substantial fall in profitability, with a 1893.89% decrease in profit. The company's net worth observed a substantial decline by a decrease of 399.38%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Catalyst Lifesciences?
In 2021, Catalyst Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 01 Nov 2021 | ₹2.55 M | Open |
How Many Employees Work at Catalyst Lifesciences?
Catalyst Lifesciences has a workforce of 0 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Catalyst Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Catalyst Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
